COMP <GO>
ARQT vs TNGX // FREE CASH FLOW YIELD
Arcutis Biotherapeutics Inc. (NASDAQ) VS. Tango Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ARQT 10
— TNGX 1
▲ FREE CASH FLOW YIELD LEADER: ARQT
LAST: $31.26 (-2.53%) • MKT CAP: $4.03B
fcf-yield
-0.16%
LAST: $21.76 (-4.22%) • MKT CAP: $3.83B
fcf-yield
-3.68%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARQT VS. TNGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARQT | TNGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 90.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.00% | -28.90% | +25.90 | ARQT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -0.16% | -3.68% | +3.52 | ARQT | /fcf-yield <GO> |
| Operating Margin | -3.30% | -60.00% | +56.70 | ARQT | /operating-margins <GO> |
| Net Profit Margin | -4.30% | -60.00% | +55.70 | ARQT | /net-margins <GO> |
| Revenue Growth (YoY) | 91.30% | 48.30% | +43.00 | ARQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.78 | 26.00 | -18.22 | TNGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | ARQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 46.9 | +19.10 | ARQT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.87 | +0.13 | ARQT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 28.0x | -4.00 | ARQT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.03B | $3.83B | $200.1M | ARQT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARQT REV | TNGX REV | ARQT GROSS % | TNGX GROSS % | ARQT FCF | TNGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $376.1M | $62.4M | 90.2% | — | -$6.3M | -$139.9M |
| FY 2024 | $196.5M | $42.1M | 90.3% | — | -$112.3M | -$132.3M |
| FY 2023 | $59.6M | $36.5M | — | — | -$249.7M | -$119.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARQT // BETA 1.00
TNGX // BETA 0.87